stars 1 stars 2 stars 3

At Corvidia Therapeutics, we are creating precision therapies by using the science of genomics in new ways. Through random genetic mutation, nature conducts experiments, subtly changing how key proteins work in our bodies and influencing the factors that drive diseases differently in different groups of patients. We study the networks of these genetic variations and how they affect specific diseases in specific patients, allowing us to understand how a personalized drug in complex diseases may behave before we ever begin a clinical trial. We believe that by leveraging the inner networks of genomics we can develop therapies tailored to patients across a range of complex diseases. Working together, our team of distinguished scientists, experienced drug developers and a successful group of investors are focused on bringing these innovations to patients.

Corvidia Therapeutics Questions

The Corvidia Therapeutics annual revenue was $12.7 million in 2026.

Marc de Garidel is the CEO of Corvidia Therapeutics.

3 people are employed at Corvidia Therapeutics.

Corvidia Therapeutics is based in Waltham, Massachusetts.

The NAICS codes for Corvidia Therapeutics are [5417, 54, 54171, 541714, 541].

The SIC codes for Corvidia Therapeutics are [873, 87].

Top Corvidia Therapeutics Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users